Floatz logo

ATENOLOL

Diabetes Mellitus

The George InstituteSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

43 Active assets in the Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Metformin
Erbil Polytechnic University
Phase 4A
Pioglitazone
Milton S. Hershey Medical Center
Phase 4BBB
Alogliptin
Takeda
Phase 3BBB
Glibenclamide
Takeda
Phase 4BBB
Aspirin
Region Skane
Phase 4BBB

View all 49 →

Same molecule, other indications

ATENOLOL is also rated in:

myocardial ischemiaDormant
BBB
Indicative · Phase 4
75 / 100
View asset →
stroke disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
hypertensive disorderDormant
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →